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One of the remaining enigmas of the dendritic cell (DC) network is the potential contribution of plasmacytoid
DCs (pDCs) to antigen presentation. Although the antigen-presentation capacity of conventional DCs (cDCs)
is clearly defined, pDCs are generally attributed as having little, if any, antigen-presentation function. Instead,
pDCs are regarded as immunomodulating cells, capable of directing the immune response through their se-
cretion of large amounts of type I interferons. In this review, we examine the evidence for a potential role of
pDC in antigen capture, processing, and presentation to T cells at sites of infection and in the lymph nodes.Introduction
The identification and characterization of dendritic cells (DCs)
provided a solution to two major immunological problems that
for a long time baffled immunologists (Steinman, 1991). First, it
identified the cells required for initiation of T cell-dependent
immune responses, a function no other cell type performs as
efficiently as DCs. Second, it described a cell capable of trans-
porting to and presenting in the lymph nodes (LNs) antigens cap-
tured in peripheral tissues, thereby providing a cellular connec-
tion between the likely points of pathogen entry and the organs
in which immune responses against those pathogens are initi-
ated. Subsequent work established that the DC network is actu-
ally composed ofmultiple subtypes that vary in hematological or-
igin, life cycle, and functional properties but that share enough
features to include them in a single family (Shortman and Naik,
2007; Villadangos and Schnorrer, 2007). One of the recognized
members of this family is the plasmacytoid DC (pDC), which is
different enough from the rest of the family to be included in asub-
group of its own, distinct from the other subtypes of ‘‘conven-
tional DC (cDC).’’ pDCs were included in the DC family relatively
recently (Cella et al., 1999; Grouard et al., 1997; Siegal et al.,
1999), but cells with characteristics of pDCs had been known
for several decades earlier as ‘‘T-cell associated plasma cells,’’
‘‘plasmacytoid T cells’’ and ‘‘natural interferon-producing cells’’
(Fitzgerald-Bocarsly et al., 2008). The latter name refers to the
only undisputedly unique feature of pDCs: their ability to quickly
secrete large amounts of type I interferons (IFN I) in response to
viral infections, owing to their constitutive expression of the tran-
scription factor IRF-7 (Fitzgerald-Bocarslyetal., 2008).To respond
to pathogens, pDCs do not need to be infected. They can detect
the unique structural features of viral nucleic acids, such as unme-
thylated CpG-rich DNA motifs or double-stranded RNA, by em-
ploying Toll-like receptors (TLRs). When TLRs engage these mo-
tifs, they initiate a signaling cascade that results in pDC activation.
In addition to secreting IFN I, activated pDCs undergo other
important phenotypic changes, notably the acquisition of a den-
dritic morphology and the upregulation of MHC and T cell costi-
mulatory molecules, which enable pDCs to engage and activate
naive T cells (Asselin-Paturel et al., 2001; Bjorck, 2001; Grouard352 Immunity 29, September 19, 2008 ª2008 Elsevier Inc.et al., 1997; Kadowaki et al., 2001; Nakano et al., 2001; O’Keeffe
et al., 2002). These are also the major changes that activated
cDCs go through when they detect pathogens, and these
changes epitomize the so-called maturation process (Reis e
Sousa, 2006). The observation that pDCs also acquire a mature
phenotype capable of naive T cell activation is what justified their
inclusion in the DC family. Because pDCs appear round in shape
rather than dendritic before activation, resting pDCs have also
been named ‘‘pre-pDCs,’’ reserving the term pDCs only for their
activated counterparts (Shortman and Naik, 2007; Soumelis and
Liu, 2006). For simplicity, in this review we will stick to the terms
immature (or resting) and mature (or activated) to refer to these
two stages of pDC development.
By secreting IFN I, pDCs can activate both the innate (e.g., nat-
ural killer cells) and the acquired (e.g., cDCs and B cells) arms of
the immune system. In addition, it is commonly accepted that
upregulation of MHC and T cell costimulatory molecules enable
mature pDCs to play a direct role in antigen presentation and
T cell activation. The mechanisms employed by pDCs to detect
pathogens, and the effects of their IFN I secretion on the immune
response, have been extensively described in excellent reviews
(Colonna et al., 2004; Fitzgerald-Bocarsly et al., 2008; Liu, 2005).
The focus of this review is to examine the evidence for a role of
pDCs in antigen capture, processing, and presentation. Neces-
sarily, a review on this aspect of pDCs must use cDCs as the
model of reference. This will allow us to evaluate the relative con-
tribution of pDCs to T cell immunity in the context of a typical im-
mune response, which probably involves the simultaneous par-
ticipation of several DC types (Villadangos and Schnorrer, 2007).
pDC Migration in the Steady State and in Response
to Infection
The life cycle andmigratory properties of cDC types vary consid-
erably, and this can have a major influence on the role of each
type in antigen capture and presentation (Villadangos and
Schnorrer, 2007). We will therefore start by recapitulating the
migratory properties of pDCs.
The pattern of pDC development and trafficking is quite differ-
ent from that of cDCs. The precursors of cDCs leave the bone
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peripheral tissues, in which they convert into resident andmigra-
tory cDCs, respectively (Shortman and Naik, 2007). Newly gen-
erated cDCs exhibit an ‘‘immature’’ phenotype dedicated to an-
tigen sampling and are characterized by low surface expression
of MHC class II (MHC II) and T cell costimulatory molecules (Vil-
ladangos and Schnorrer, 2007). The resident cDCs will spend
their entire lifespan in this immature state unless they receive
activation signals, in which case they undergo profound changes
that culminate in the acquisition of a ‘‘mature’’ phenotype (Wil-
son et al., 2003). The migratory cDCs traffic from the tissues to
the local LNs via the afferent lymph and become mature upon
reaching the LNs (Villadangos and Schnorrer, 2007). This migra-
tion and maturation occur constitutively, even in the absence of
germs or when the cDCs are incapable of responding to TLR sig-
naling (Wilson et al., 2008), suggesting a role for migratory DCs in
the transport of peripheral self-antigens to induce T cell toler-
ance (Reis e Sousa, 2006; Steinman and Nussenzweig, 2002).
Most of the cDCs do not leave the spleen or the LNs (see also
Alvarez et al. (2008) in this issue of Immunity).
In contrast to the cDCs, the pDCs develop fully in the bone
marrow and then enter the bloodstream (Shortman and Naik,
2007) (Figure 1). In the steady state, the pDCs are present in
the thymus and all secondary lymphoid organs (Asselin-Paturel
et al., 2003; Bendriss-Vermare et al., 2001; Okada et al., 2003;
Summers et al., 2001), but they are difficult to detect in most
peripheral tissues (De Heer et al., 2004; Wollenberg et al.,
2002). This has led to the notion that pDCs enter the spleen
and LNs through the blood but not via the lymph (Randolph
et al., 2008), a view supported by the apparent lack of pDCs in
gut and liver afferent lymph collected from cannulated rats (Yrlid
et al., 2006). However, a recent report has described pDCs in
afferent lymph of noninflamed skin of sheep and pigs and in
a similar proportion relative to cDCs to that observed in the blood
or the lymphoid organs (Pascale et al., 2008). It is unclear why the
pDCs were detected in the lymph of large mammals but not rats;
this may have been because of species-intrinsic differences or
different amounts of pathogen exposure in the animals used in
each study (Pascale et al., 2008). Another explanation might be
that although the pDCs can access multiple tissues, they are re-
tained in some but not others. Indeed, although pDCs are rare in
the skin (Wollenberg et al., 2002) and the lungs (De Heer et al.,
2004), they are abundant in the intestine (Wendland et al.,
2007) and the kidneys (Woltman et al., 2007). Perhaps the
pDCs that enter the skin leave shortly afterward via lymph,
whereas those entering the gut leave more slowly or not at all;
this might explain the contrast in pDC numbers in afferent lymph
collected from the skin and the gut. The notion that, in the ab-
sence of infection, substantial numbers of pDCs enter
peripheral tissues beforemigrating to LNswill need to be corrob-
orated in more experimental systems. If confirmed, this notion
has important implications. It means that pDCs may be able to
play a more important role in early detection of pathogens in pe-
ripheral tissues than is usually appreciated. It also means that
pDCs, like migratory cDCs, may contribute to the transport of
self-antigens from peripheral tissues to the LNs in the steady
state (De Heer et al., 2004). Whether pDCs play a direct role in
induction of peripheral tolerance to those antigens remains
uncertain, because they do not appear to undergo maturation(De Heer et al., 2004), a requirement for pDC-mediated T cell
stimulation.
Pathogen-associated molecules or inflammatory mediators
exert a dramatic effect on pDC trafficking, causing pDC accumu-
lation in the tissues from which these signals are released and in
the corresponding draining LNs. For instance, pDCs accumulate
(1) in the lungs and mediastinal LNs of mice infected with influ-
enza virus (Geurtsvankessel et al., 2008) or respiratory syncytial
virus (Smit et al., 2006; Wang et al., 2006), (2) in the subcutane-
ous LNs of mice infected in the skin with Leishmania major (Bald-
win et al., 2004) or in the footpad with herpes simplex virus 1
(Smith et al., 2003), and (3) in the vaginal mucosa ofmice infected
with herpes simplex virus 2 (Lund et al., 2006; Shen and Iwasaki,
2006). They are also abundant in inflamed human LNs (Cella
et al., 1999) and skin lesions (Wollenberg et al., 2002) and are
Figure 1. Migratory Behavior and Antigen-Presenting Properties of
pDCs in Steady State and Inflammatory Environments
In the steady state, pDCs are produced in the bone marrow and disseminate
via the blood to the thymus and the secondary lymphoid organs (spleen, not
shown, and the lymph nodes [LNs]). Because pDCs are difficult to detect in
most peripheral tissues, it is generally assumed that their primary route of entry
into the LNs is through the blood via the high endothelial venules and not by
means of the lymph, although new evidence suggests otherwise (see main
text for details). Detection of activating signals (e.g., viruses) induces pDCs ac-
cumulation at the infection site and associated draining LNs. Activated pDCs
secrete large amounts of IFN I and undergo maturation. Mature pDCs acquire
dendritic morphology and upregulate MHC and T cell costimulatory mole-
cules, so they have the potential to present antigens via MHC I and II to
CD8+ and CD4+ T cells, respectively. However, it is still controversial whether
pDCs have a direct role in antigen processing and presentation to T cells, in
particular via the MHC I crosspresentation pathway. Such a role appears to
be exerted primarily at the inflammation site rather than at the draining lymph
node.Immunity 29, September 19, 2008 ª2008 Elsevier Inc. 353
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the proinflammatory TLR7 ligand imiquimod (Palamara et al.,
2004; Urosevic et al., 2005). The simultaneous accumulation of
pDCs in infected tissues and draining LNs might be interpreted
as further evidence of pDC migration from the tissues to the LN
via the lymph. The reality, however, is not so simple. Most of
the pDCs accumulating in inflamed LNs enter via high endothelial
venules (Cella et al., 1999; Grouard et al., 1997; Yoneyama et al.,
2004). Of the pDCs recruited to peripheral infected tissues, few
appear to migrate to LNs, and they only do so relatively late after
the onset of infection (Geurtsvankessel et al., 2008). Furthermore,
whereas viral infectionof sheepskin increased the rateof cDCmi-
gration from skin to LNs, it did not alter the rate of pDCmigration
(Pascale et al., 2008). Therefore, the migratory behavior of pDCs
is more consistent with a role in antigen presentation and/or im-
munomodulation at sites of infection or inflammation rather
than with a role in antigen transport to the local LNs for presenta-
tion to T cells. This latter function appears to be carried out
predominantly by the cDCs (Villadangos and Schnorrer, 2007).
Simultaneous recruitment of blood pDCs to the LNs draining
the infected site probably serves to promote the formation of an
immunostimulatory environment via secretion of type I IFN.
T Cell Activation by pDCs
Before reviewing the work that has been performed to address
the antigen-presenting capabilities of pDCs, it is important we
clarify how we will use some terms. ‘‘Antigen presentation’’ is
used in the literature to refer to two related but distinct phenom-
ena. The first refers to the intracellular processes that culminate
in exposure of MHC-peptide complexes on the surface of an
antigen-presenting cell (APC). For this to happen, the APC has
to synthesize, or capture from the extracellular medium, the pre-
cursor polypeptide, degrade it to generate antigenic peptides,
and load those peptides ontoMHCmolecules. In its second con-
notation, antigen presentation refers to events that follow the
recognition of MHC-peptide complexes by T cells, for instance
T cell proliferation and cytokine secretion. Studies that measure
antigen presentation from the latter perspective are less con-
cerned with the intracellular mechanisms underlying formation
of MHC-peptide complexes. Such complexes may be artificially
generated by incubating the APCwith a synthetic peptide ormay
correspond to allogeneic MHC molecules. We will refer to this
second connotation of antigen presentation as T cell activation
or stimulation. If the responding T cells are naive, activation
requires costimulatory signals in addition to MHC-peptide com-
plexes, and this is usually termed priming to distinguish it from
activation of memory T cells or T cell hybridomas, which are
considered to be less dependent of costimulation. Antigen
recognition by naive T cells does not necessarily lead to an effec-
tor immune response. The outcome can also be tolerogenic,
leading to differentiation of regulatory or suppressor T cells,
T cell anergy, or abortive T cell proliferation, depending on the
signals encountered at the time of antigen recognition (Reis e
Sousa, 2006; Steinman et al., 2003). Although activation and
priming are terms that are usually associated with immunity, in
this review we will also use them to refer to the induction of
T cell tolerance.
Distinguishing between the two connotations of antigen pre-
sentation is important because many studies that reportedly354 Immunity 29, September 19, 2008 ª2008 Elsevier Inc.measured ‘‘antigen presentation’’ by pDCs were in fact assess-
ing T cell activation, either in vitro or upon adoptive transfer
in vivo. In many of these studies, the MHC-peptide complexes
recognized by the T cells were MHC allotypes or were generated
by incubation with synthetic peptides. This is not to say that such
studies are not important. They have revealed what pDCs might
do provided that they present antigens, and this information may
be useful to design therapies based on adoptive transfer of pep-
tide-antigen-loaded pDCs. An important limitation of these stud-
ies, however, is that they do not necessarily providemuch insight
on what pDCs actually do in physiological conditions, in which
T cell activation must be preceded by antigen processing and
presentation.
There has been some controversy regarding whether pDCs
are capable of priming. The consensus now is that they can ac-
tivate naive T cells, as well as memory T cells, if they undergo
maturation (Colonna et al., 2004; Liu, 2005). The expression of
MHC and T cell costimulatory molecules on activated pDCs is
not as high as on their cDC counterparts, and this is probably
why pDCs tend to be less efficient at T cell priming than cDCs.
Nevertheless, pDCs can stimulate immunity upon adoptive
transfer (Salio et al., 2004; Schlecht et al., 2004), or sustain
protective responses at sites of infection (McGill et al., 2008),
demonstrating their immunogenic potential. Several reports
have indicated that pDCs can also induce T cell tolerance, pri-
marily through the induction of regulatory T cells, a capacity
they also share with cDCs (Gilliet and Liu, 2002; Goubier et al.,
2008 [in this issue]; Ito et al., 2007; Martin et al., 2002; Ochando
et al., 2006; Sharma et al., 2007). This may enable pDCs to pro-
mote regulatory T cell formation within the infection site to
dampen the immune response and prevent immunopathology
(De Heer et al., 2004; Smit et al., 2006; Wang et al., 2006). How-
ever, as in the case of cDCs, the factors that determine whether
the T cells primed by pDCs will differentiate into effector or
regulatory T cells remain ill defined.
Because the pDCs are capable of T cell stimulation, it might be
expected that to show antigen presentation by this DC type
would simply require incubating the pDCs with an antigen and
antigen-specific T cells and measuring the subsequent T cell re-
sponse as a readout of MHC-peptide-complex formation. When
this experiment is carried out employing cDCs, detection of
MHC-peptide complexes is relatively straightforward. However,
pDCs perform very poorly in this type of experiment, even after
correcting for the lower T cell stimulatory capacity of pDCs. In-
deed, few reports have actually demonstrated an important role
for pDCs in antigen presentation either in vitro or in vivo. This
speaks of a clear difference that exists in antigen-presentation
function between cDCs and pDCs and that cannot be explained
only by differences in MHC expression. What is the basis for this
difference? In the following sections, we will dissect what we
know about the ability of pDCs to deliver different forms of anti-
gen to the MHC I and II presentation pathways and to produce
MHC-peptide complexes.
Presentation of Endogenous Antigens by pDCs
There is no question that pDCs present antigens because they
express both MHC I and II molecules. What is not clear is how
efficient they are at presenting different types of antigen, espe-
cially when compared to cDCs. Antigens expressed by APCs
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compartments in which proteases generate MHC peptide li-
gands (Wilson and Villadangos, 2005). These compartments
are primarily the cytosol for peptides presented by MHC I mole-
cules and the endosomal route for those presented by MHC II.
Virtually any endogenous protein can occur in the cytosol as
a full-length protein or a defective ribosomal product (Yewdell
and Nicchitta, 2006), soMHC Imolecules can potentially present
peptides derived from any protein made by the APC, even those
that are normally secreted. The repertoire of endogenous pro-
teins that can be presented via MHC II is more restricted be-
cause not all these proteins access endocytic compartments.
Those that are normally expressed on the plasma membrane,
or in the endosomal route itself, comprise the majority of these
proteins because they are turned over by proteolytic degradation
in endosomes and lysosomes (Wilson and Villadangos, 2005).
Cytosolic proteins can also enter endosomes by autophagy (Pal-
udan et al., 2005; Schmid et al., 2007) or other transporting
mechanisms (Zhou et al., 2005), and cDCs exploit this route to
present cytosolic proteins via MHC II.
Several studies have shown that pDCs efficiently present en-
dogenous antigens via MHC I and II molecules, whether the an-
tigens are constitutively expressed (Krug et al., 2003; Young
et al., 2008) or derived from viruses infecting the pDC (Fonteneau
et al., 2003; Salio et al., 2004; Schlecht et al., 2004; Young et al.,
2008). These studies confirm that the antigen-presentation
machinery of pDC is operative and produces peptide-loaded
MHC I and II molecules as in cDC and other APCs. Autophagy
allows pDCs to detect viral nucleic acids synthesized in the cyto-
sol by employing endosomal TLRs (Lee et al., 2007). It is likely
that this mechanism also allowsMHC II presentation of cytosolic
antigens in pDCs as it does in cDCs (Paludan et al., 2005), but
this has yet to be demonstrated.
Mechanisms of Exogenous Antigen Uptake in pDCs
The category of antigens that pDCs seem to present poorly is ex-
ogenous—antigens that have to be captured from the extracel-
lular environment. These are the antigens that cDCs present
with higher efficiency than any other APCs, with the exception
of antigen-specific B cells (see below). There are three features
that make cDCs particularly efficient at exogenous antigen pre-
sentation: high endocytic activity, ability to retain on their surface
long-livedMHC II-peptide complexes, and the capacity to cross-
present. How do pDCs compare?
The cDCs can internalize extracellular material by macropino-
cytosis, phagocytosis, and receptor-mediated endocytosis, the
latter two facilitated by the expression of multiple types of recep-
tors (Villadangos and Schnorrer, 2007). This makes cDCs ‘‘all-
purpose’’ APCs, capable of capturing virtually any extracellular
material (e.g., soluble proteins, glycosylated compounds, immu-
nocomplexes, artificial particles, cells, bacteria, nucleic acids,
etc). Overall, pDCs do not appear as endocytic as cDCs, but
this is still a matter of contention. Several mouse and human
studies concluded that pDCs cannot phagocytose dead cells,
zymosan, or artificial particles (Dalgaard et al., 2005; Grouard
et al., 1997; Robinson et al., 1999; Stent et al., 2002), but other
studies concluded the opposite (Hoeffel et al., 2007; Ochando
et al., 2006). This controversy is reminiscent of former discus-
sions on the phagocytic capacity of cDCs; all of these discus-sions were settled with the realization that phagocytosis is devel-
opmentally regulated in this DC type (Steinman and Swanson,
1995). Subtle differences in the material used to measure pDC
phagocytosis, or in pDC origin or assay conditions, may account
for the contrasting results of different groups. Perhaps the pDCs
only phagocytose if they receive signals through specific recep-
tors, and these were not engaged in all studies. Whatever the
reason, this remains a matter for future investigation.
Analysis of uptake of soluble proteins by pDCs has provided
more consistent results, with several studies concluding that
pDCs efficiently capture ovalbumin (OVA) or hen egg lysozyme
(HEL) in vitro and in vivo (De Heer et al., 2004; Sapoznikov
et al., 2007; Young et al., 2008). Soluble proteins can be internal-
ized by macropinocytosis or receptor-mediated endocytosis.
The macropinocytic activity of pDCs, as measured by uptake
of dextran or lucifer yellow, is rather poor (Ito et al., 1999; Robin-
son et al., 1999), so uptake of OVA and HEL is most likely to be
mediated by micropinocytosis or a surface receptor.
There has been considerable interest in recent years on the
identification of potential antigen receptors expressed by pDCs
as well as cDCs because these molecules represent attractive
targets for vaccine delivery (Bonifaz et al., 2004; Corbett et al.,
2005). Several pDC receptors have been characterized that,
when targeted with antibodies coupled to antigens, mediate en-
docytosis, processing, and presentation of the antigen; exam-
ples of such receptors are BDCA-2, Siglec-H, andDCIR (Dzionek
et al., 2001; Jaehn et al., 2008; Meyer-Wentrup et al., 2008;
Zhang et al., 2006). These molecules are representatives of the
C-type lectin (CLR) and sialic-acid-binding immunoglobulin-like
lectin (Siglec) families of receptors (Crocker et al., 2007; Robin-
son et al., 2006), which along with the triggering receptors ex-
pressed on myeloid cells (TREM) (Klesney-Tait et al., 2006)
may play important roles in pathogen recognition similar to those
played by TLRs (Trinchieri and Sher, 2007), NOD-like receptors,
and RIG-like helicases (Meylan et al., 2006). However, currently
little is known about the natural ligands of most of the CLRs, Sig-
lecs, and TREMs. The ligands may not even be pathogen-asso-
ciated molecular patterns but self components, and the primary
role of these receptorsmay not be to capture antigens but to trig-
ger immunomodulatory signals. Indeed, BDCA-2, Siglec-H, and
DCIR crosslinking initiates a signaling cascade in pDC that in-
hibits IFN type I production (Blasius et al., 2004; Cao et al.,
2007; Dzionek et al., 2001; Meyer-Wentrup et al., 2008; Rock
et al., 2007). Thus, the function of these three receptors may
be to detect self components released by damaged tissues at
sites of inflammation and inhibit IFN I secretion to prevent immu-
nopathology (Swiecki and Colonna, 2007). Similar inhibitory
roles have been described for the receptors ILT-7 and NKp44
(Brown et al., 2004; Cao et al., 2006), but again, whether these
molecules have an antigen-receptor function remains uncertain.
Another potential pDC antigen receptor is the surface mole-
culeBST-2, also knownasCD317 orHM1.24. This is a commonly
used marker of pDCs recognized by the mAbs PDCA-1 and
120G8 (Blasius et al., 2006). BST-2 has been recently described
as a ‘‘tetherin’’ that holds newly formed virions on the surface of
infected cells to limit viral spread (Neil et al., 2008). It also medi-
ates endocytosis of virions, so it may function as a receptor for
presentation of antigens contained in viral particles. In support
of this hypothesis, an antigen coupled to the mAb PDCA-1 wasImmunity 29, September 19, 2008 ª2008 Elsevier Inc. 355
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a function of BST-2 in presentation of natural ligands is lacking.
A group of receptors whose role in antigen capture and pre-
sentation is better established are the immunoglobulin receptors
(FcRs). FcRII (CD32) is expressed on pDCs, and this receptor has
been shown to mediate internalization of immunoglobulins
bound to chromatin (Means et al., 2005), Coxsackie virus
(Wang et al., 2007), the model antigen KLH (Benitez-Ribas
et al., 2006), and the tumor antigen NY-ESO-1 (Schnurr et al.,
2005). The DNA immunocomplexes, and the RNA contained in
the opsonised virus, could thus access endosomal TLRs (TLR7
and TLR9), trigger pDC activation, and promote IFN I secretion.
In the case of chromatin uptake, this mechanism may contribute
to the development of systemic lupus erythematosus. It is rea-
sonable to speculate then that the activated pDCs may also
present antigens captured with their FcRs, as cDCs do (Boule
et al., 2004; den Haan and Bevan, 2002; Kalergis and Ravetch,
2002; Regnault et al., 1999 and reviewed in Nimmerjahn and
Ravetch, 2007). Indeed, those studies that did measure MHC II
presentation of immunocomplexed antigens (KLH or NY-ESO-1)
showed that pDC could present these two antigens (Beni-
tez-Ribas et al., 2006; Schnurr et al., 2005). However, for KLH
the efficiency of this presentation was not compared in detail
to that of cDCs, whereas NY-ESO-1 was presented an order of
magnitude more efficiently by cDCs.
The conclusion of these studies is that, despite the abundance
of putative antigen receptors on the pDC surface, which of these
receptors, if any, actually contribute to antigen uptake and
presentation remains an open question.
Generation and Turnover of MHC II-Peptide Complexes
in pDCs
The second specialization that makes cDCs highly efficient
APCs concerns the regulation of their MHC II presentation path-
way. Immature cDCs constitutively produce and deliver to their
plasma membrane MHC II-peptide complexes, but the number
of these complexes on the cell surface remains constant be-
cause arrival of new complexes is matched by endocytosis
and endosomal degradation of pre-existing ones (Cella et al.,
1997; Veeraswamy et al., 2003; Villadangos et al., 2001; Wilson
et al., 2004; Zwickey et al., 2006 and reviewed in Villadangos
et al., 2005). MHC II-peptide complex turnover is regulated by
MHC II b chain ubiquitination (Ohmura-Hoshino et al., 2006;
Shin et al., 2006; van Niel et al., 2006), a reaction mediated by
the ubiquitin ligase March I (De Gassart et al., 2008; Matsuki
et al., 2007; Thibodeau et al., 2008; Young et al., 2008), amember
of the March family of membrane-bound ubiquitin ligases (also
known as c-mir) (Goto et al., 2003; Ohmura-Hoshino et al.,
2006). Upon encounter of activation signals, maturing cDCs tran-
siently increase antigen uptake (West et al., 2004) and upregulate
synthesis of MHC II molecules, which are preferentially delivered
to the endosomal compartments that contain foreign antigens
(Blander and Medzhitov, 2006). MHC II synthesis is later down-
regulated because expression of CIITA, the master transcription
factor of the MHC II presentation machinery, is silenced in ma-
ture cDCs (Landmann et al., 2001). In step with this change in
MHC II synthesis, MHC II-peptide complex turnover is downre-
gulated during cDC maturation (Cella et al., 1997; Veeraswamy
et al., 2003; Villadangos et al., 2001; Wilson et al., 2004; Zwickey356 Immunity 29, September 19, 2008 ª2008 Elsevier Inc.et al., 2006). This enables mature cDCs to display on their sur-
face long-lived MHC II molecules loaded with peptides derived
from antigens captured at the time of activation (Villadangos
et al., 2005). However, this comes at a cost: Mature cDCs lose
their ability to present viaMHC II newly encountered antigens, in-
cluding those exogenous antigens that they can still endocytose,
such as soluble proteins (Young et al., 2007), and endogenous
antigens derived from transfected nucleic acids (Gilboa, 2007;
Morse et al., 1998) or infecting viruses (Young et al., 2007). It is
important to realize that what makes cDCs so efficient at presen-
tation of exogenous antigens is not somuch a special capacity to
generateMHC II-peptide complexes as is their ability to retain on
their cell surface, for long periods of time, those complexes that
were generated during the crucial period after antigen uptake
and activation, a period during which availability of peptide-
receptive MHC II molecules is temporarily boosted through
increased synthesis (Villadangos et al., 2005).
The developmental changes in MHC II presentation described
for cDCs do not occur in pDCs. First, CIITA transcription is con-
trolled in pDCs by a different promoter (pIII) than the one used by
cDCs (pI), and the pIII promoter is not silenced upon pDC activa-
tion (LeibundGut-Landmann et al., 2004). MHC II synthesis and
peptide loading is thus maintained in activated pDCs (Young
et al., 2008). Second, MHC II ubiquitination and turnover are
not downregulated in activated pDCs (Young et al., 2008). This
means that pDCs lack the ability to accumulate long-lived
MHC II-peptide complexes generated shortly after activation.
This is probably one, if not the most important, factor that pre-
vents pDCs from presenting limiting amounts of exogenous an-
tigens as efficiently as cDCs. Thus, even in cases in which both
pDCs and cDCs capture in the periphery comparable amounts of
a ‘‘bolus’’ of inoculated antigen, only cDCs present this antigen in
the LN (De Heer et al., 2004). Naturally, if the amount of antigen
captured by the pDCs is sufficiently high, presentation is detect-
able, as probably happens when the antigen is targeted to a sur-
face molecule (Dzionek et al., 2001; Meyer-Wentrup et al., 2008;
Sapoznikovet al., 2007;Schnurr et al., 2005; Zhanget al., 2006) or
if it is constantly available at a relatively high concentration in the
extracellular medium (Young et al., 2008). Thismay be the reason
why pDCs recruited to organ grafts can present alloantigens
(Ochando et al., 2006). Importantly, continued MHC II-peptide
complex formation and turnovermay provide pDCs some advan-
tages over the cDCs. For instance, at sites of infection or inflam-
mation, the pDCs may be able to continually display to newly
arriving T cells updated information about the repertoire of exog-
enous antigens contained in the surrounding environment.
A form of antigen that can be available for long periods and in
high supply is that synthesized by the pDCs themselves—en-
dogenous antigens—which, as mentioned above, are efficiently
presented by pDCs. The pDCs clearly have an advantage over
cDCs when it comes to MHC II presentation of this category of
antigens. Whereas cDCs that become infected with viruses after
reaching the mature state have compromised their capacity to
present endogenous viral antigens via MHC II (Young et al.,
2007), infected activated pDCs maintain presentation of these
antigens (Young et al., 2008). Again, this may allow pDCs to
play a role in MHC II presentation of viral antigens within the in-
fection site rather than in the draining LN (Geurtsvankessel et al.,
2008).
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MHC II antigen-presentation machinery in a manner that is qual-
itatively distinct to that described for cDCs. This is in itself suffi-
cient evidence to support the notion that the roles of cDCs and
pDCs in antigen presentation to CD4+ T cells are not just quan-
titatively different, but complementary and, most likely, largely
nonoverlapping.
Can pDCs Crosspresent?
The third property that makes cDCs highly efficient APCs is their
ability to crosspresent, that is, to present exogenous antigens on
their MHC I molecules (Wilson and Villadangos, 2005). Not all
cDCs appear equally capable of crosspresentation (Villadangos
and Schnorrer, 2007). However, the reason for this heterogeneity
is controversial. Some studies suggest that crosspresentation
requires specialized machinery that is only expressed in some
cDC types (predominantly, in mice, the CD8+ DCs [Dudziak
et al., 2007; Pooley et al., 2001; Schnorrer et al., 2006]). Other
studies suggest that multiple types of cDCs may be capable of
crosspresentation provided they capture the antigen employing
the right receptor (Burgdorf and Kurts, 2008) or are properly
stimulated at the time of antigen capture (Backer et al., 2008;
den Haan andBevan, 2002).Whether pDCs are able to crosspre-
sent is a controversial and unresolved matter. Several studies
have shown that mouse pDCs do not possess the capacity
to crosspresent (Jaehn et al., 2008; Salio et al., 2004; Sapoznikov
et al., 2007) or that their capacity is negligible when compared
to cDCs (Shinohara et al., 2006). In at least two of these studies,
the lack of crosspresentation could not be attributed to poor
antigen uptake because the pDCs presented the antigen via
MHC II (Jaehn et al., 2008; Sapoznikov et al., 2007). This conclu-
sion is consistent with a number of reports that showed that
crosspriming of CD8+ T cells in vivo against viruses or intracellu-
lar bacteria is exerted by cDCs, with no detectable involvement
of pDCs (Belz et al., 2005; Belz et al., 2004a; Belz et al., 2004b;
Smith et al., 2003 and reviewed in Villadangos and Schnorrer,
2007).
The crosspresenting capacity of human pDCs has only been
assessed in vitro. The tumor antigen NY-ESO-1 in soluble
form, associated to immunoglobulins or formulated in the adju-
vant iscomatrix, was not crosspresented by human pDCs, al-
though at least the immunocomplexed antigen was presented
via MHC II (Schnurr et al., 2005). In contrast, two studies have
reported crosspresentation of lipopeptides, cell-associated anti-
gens, and viral particles by human pDCs (Di Pucchio et al., 2008;
Hoeffel et al., 2007). Strikingly, the crosspresentation pathway
employed by the pDCs in each of these studies was different:
In the earlier study, the pDCs used the ‘‘cytosolic’’ protea-
some-dependent pathway, whereas in the latter, they relied on
the ‘‘endosomal’’ pathway (Rock and Shen, 2005). At present it
is difficult to give an explanation for the contrasting results of
the different mouse and human studies. The same arguments
that have been used to explain the differential crosspresentation
capabilities of distinct cDC types may be applicable here: Per-
haps the pDCs only crosspresent antigens captured via some re-
ceptors or if stimulated by yet poorly-defined factors. Whatever
such factorsmight be, the fact of thematter is that currently there
is no strong evidence supporting a role for pDC-mediated cross-
presentation in vivo.Conclusion: How ‘‘Dendritic’’ Are pDCs?
The picture that emerges from the studies we have reviewed is
sobering: We know that pDCs can have powerful immunomodu-
latory roles when they display cognate antigens to T cells, and
yet we know very little about their real antigen-presenting func-
tions in vivo. Why is this? By definition, pDCs are ‘‘professional’’
APCs, a category of cells that includes not only cDCs but also B
cells and macrophages. The antigen-presenting properties of
cDCs, B cells, and macrophages, and the role that antigen pre-
sentation by these cell types plays on the immune response, are
now well characterized. Why is this not the case for pDCs? One
reason we would like to suggest is that perhaps the research on
pDC function has been too dominated by the view that pDCmust
play cDC-like roles. However, it is now clear that the way pDCs
capture and handle antigens, and exploit their antigen-presenta-
tion machinery, is quite distinct from that described for cDCs.
To illustrate the current status of the field, we could imagine
howwewould think about B cells if we did not know that their pri-
mary role as APCs is to present antigens captured with their sur-
face immunoglobulin. Indeed, B cells are as efficient, or more,
than cDCs at presenting antigens recognized by this specialized
device (Lanzavecchia, 1990), but the antigen-presenting capac-
ity of polyclonal B cells appears extremely poor when compared
to that of cDCs (Schnurr et al., 2005). If the B cell receptor were
not known, stimulated B cells would appear to be very good pro-
ducers of a powerful immunomodulatory protein (antibodies),
whose production was somewhat connected to the B cell ability
to communicate with T cells, but we would not understand the
basis for this communication. Perhaps something similar
happens with our understanding of pDC function. They may be
specialized at presenting a very specific category of antigens,
rather than serving a ‘‘multipurpose’’ antigen-presentation func-
tion, which is what cDCs do best. We are not suggesting that
pDCs play similar roles to B cells (let alone that they should be
renamed ‘‘B cell-like plasmacytoid dendritic cells’’!). However
what we would like to propose is that pDCs represent a distinct
type of professional APC, different enough from cDCs to
consider them a separate entity.
If pDCs are a distinct type of APC, what is their distinct func-
tion? One role suggested by the published record might be to
present, at the infection site, endogenous antigens derived
from viruses infecting the pDCs themselves (Geurtsvankessel
et al., 2008; McGill et al., 2008). Another potential role might be
to present, again locally, exogenous antigens captured with still
uncharacterized receptors, in a manner analogous to B cells.
One interesting possibility might be that such antigens are viral
particles (virions) (Di Pucchio et al., 2008; Neil et al., 2008),
a form of antigen whose presentation has been little studied. Al-
ternatively, the antigens may be self components. In any case,
the consequences of such presentation may be to promote
T cell immunity or to dampen ongoing immune responses, given
that there is evidence supporting either outcome (see above).
Admittedly, these hypotheses are based on a limited number
of studies and need further testing to confirm or discard them.
Inflammation does not only recruit pDCs, but also monocyte-
derived cDCs (Alvarez et al., 2008), and these have also been
shown to present viral antigens in the infection site (Wakim
et al., 2008). The ‘‘acid test’’ for the suggestion that pDCs are
endowed with a unique APC function should be an infection (orImmunity 29, September 19, 2008 ª2008 Elsevier Inc. 357
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in T cell activation, or at least a unique complementary role to
that played by cDCs or other APCs. Such situations have not
yet been described. Indeed, pDC elimination had little impact
on CD4+ T cell responses against herpes simplex virus infection
of the vaginal mucosa (Lund et al., 2006) and on CD8+ T cell
responses against influenza virus infection of the airways
(Geurtsvankessel et al., 2008). This may mean that our hypothe-
sis is wrong, or it maymean that we have not yet come across the
right model of infection in which pDCs may play a direct role in
antigen presentation. After all, the number of models of patho-
gen infection available to immunologists is rather limited. Studies
of additional models may be required if we are to obtain a full
understanding of the antigen-presenting functions of pDCs.
The questions we have poised in this review will surely be
answered in near future; it is likely that some of the answers
will be unexpected.
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